TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15185314

Group type: EXPERIMENTAL
Intervention: PEG IFN‐alpha plus ribavirin (n = 20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: PEG IFN‐alpha monotherapy (n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Untreated subjects (n = 14)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Treated subjects (both PEG IFN‐alpha plus ribavirin and PEG IFN‐alpha monotherapy)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Treated subjects with sustained virological responses
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Treated subjects who developed chronic infection
Number of subjects: 40
Study: 11471091

Group type: EXPERIMENTAL
Intervention: Children with a parental history of myopia
Number of subjects: 153

Group type: COMPARATOR
Intervention: Children without a parental history of myopia
Number of subjects: 153
Study: 9664985

Group type: EXPERIMENTAL
Intervention: UDCA 15 mg/kg per day
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 7626348

Group type: EXPERIMENTAL
Intervention: Plasma proatrial natriuretic factor (1-98) concentration
Number of subjects: 64
Study: 2571501

Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not on chronic nifedipine therapy)
Number of subjects: 0
Study: 321103

Group type: EXPERIMENTAL
Intervention: buprenorphine hydrochloride 0.2 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: buprenorphine hydrochloride 0.4 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: morphine sulphate 5 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: morphine sulphate 10 mg
Number of subjects: 40
Study: 31132582

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DESs)
Number of subjects: 10072
Study: 28373633

Group type: EXPERIMENTAL
Intervention: Structured writing (n=10; 70% female)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Assessment only control group (n=12; 67% female)
Number of subjects: 22
Study: 26083005

Group type: EXPERIMENTAL
Intervention: Rabipur
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Verorab
Number of subjects: 90
Study: 24645908

Group type: EXPERIMENTAL
Intervention: Whole genome sequencing (WGS)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 200
Study: 22573933

Group type: EXPERIMENTAL
Intervention: Pasireotide 200-1200 μg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Pasireotide 1-1200 μg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Pasireotide
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 19485982

Group type: EXPERIMENTAL
Intervention: Standard-dose peginterferon-alpha-2b (1.5 microg/kg/week) plus low-dose ribavirin (200 mg/day) for extended 24 weeks (group A)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Low-dose peginterferon-alpha-2b (0.75 microg/kg/week) plus low-dose ribavirin for extended 48 weeks (group B)
Number of subjects: 34

Group type: COMPARATOR
Intervention: No extended treatment (group C)
Number of subjects: 34
Study: 17590184

Group type: EXPERIMENTAL
Intervention: Number of injury mechanisms reported
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Home hazards
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Duration of exclusive breastfeeding
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Maternal involvement-responsiveness
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Home organization
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Maternal paid work
Number of subjects: 394
Study: 15362963

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 64
Study: 11732026

Group type: EXPERIMENTAL
Intervention: Postoperative oral antibiotics (penicillin VK, 500 mg every 6 hours for 5 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (oral placebo, same schedule as group 1)
Number of subjects: 30
Study: 9885688

Group type: EXPERIMENTAL
Intervention: 10 micrograms sufentanil added to 7.5 mg bupivacaine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 15 micrograms fentanyl added to 7.5 mg bupivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: 7.5 mg bupivacaine alone
Number of subjects: 60
Study: 8004297

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 800 micrograms by Turbuhaler
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2129838

Group type: EXPERIMENTAL
Intervention: 800 mg at night
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: 400 mg at night
Number of subjects: 282

Group type: COMPARATOR
Intervention: 400 mg twice daily
Number of subjects: 282
Study: 874649

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 31331754

Group type: EXPERIMENTAL
Intervention: University of Wisconsin (UW) solution
Number of subjects: 81

Group type: COMPARATOR
Intervention: Histidine-tryptophan-ketoglutarate (HTK) solution
Number of subjects: 81
Study: 28441077

Group type: EXPERIMENTAL
Intervention: Conbercept
Number of subjects: 35

Group type: COMPARATOR
Intervention: Ranibizumab
Number of subjects: 35
Study: 23731453

Group type: EXPERIMENTAL
Intervention: Topical sildenafil (10%) ointment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23161898

Group type: EXPERIMENTAL
Intervention: Cisplatin (75 mg/m2 d1) and pemetrexed (500 mg/m2 d1) q3 weeks
Number of subjects: 132

Group type: COMPARATOR
Intervention: Cisplatin (50 mg/m2 d1 + 8) and vinorelbine (25 mg/m2 d1, 8, 15, 22) q4 weeks
Number of subjects: 132
Study: 21795671

Group type: EXPERIMENTAL
Intervention: Lace-up ankle braces
Number of subjects: 1460

Group type: COMPARATOR
Intervention: Control group (no braces)
Number of subjects: 1460

Group type: EXPERIMENTAL
Intervention: Lace-up ankle braces (for players with previous ankle injury)
Number of subjects: 1460

Group type: COMPARATOR
Intervention: Control group (for players with previous ankle injury)
Number of subjects: 1460

Group type: EXPERIMENTAL
Intervention: Lace-up ankle braces (for players without previous ankle injury)
Number of subjects: 1460

Group type: COMPARATOR
Intervention: Control group (for players without previous ankle injury)
Number of subjects: 1460

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1460
Study: 19349544

Group type: EXPERIMENTAL
Intervention: Adjuvant systemic therapy
Number of subjects: 3799
Study: 16775558

Group type: COMPARATOR
Intervention: Treadmill walking
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Overground walking
Number of subjects: 23
Study: 17409841

Group type: EXPERIMENTAL
Intervention: Bortezomib 1.0 mg/m on days 1, 4, 8, and 11 plus docetaxel 75 mg/m on day 1, cycled every 21 days.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Bortezomib plus docetaxel
Number of subjects: 36
Study: 10468521

Group type: EXPERIMENTAL
Intervention: High-pressure balloon inflation (15 to 20 atm)
Number of subjects: 934

Group type: COMPARATOR
Intervention: Low-pressure balloon inflation (8 to 13 atm)
Number of subjects: 934
Study: 8935812

Group type: COMPARATOR
Intervention: Olanzapine 10 mg/day (Olz10.0)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Olanzapine 1 mg/day (Olz1.0)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study: 1743840

Group type: EXPERIMENTAL
Intervention: Functional treatment with a newly designed brace
Number of subjects: 200

Group type: COMPARATOR
Intervention: Operation
Number of subjects: 200
Study: 7181299

Group type: EXPERIMENTAL
Intervention: Sulphate (1 mg m‐3)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Sulphate (0.1 mg m‐3)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Carbachol after sulphate exposure
Number of subjects: 33

Group type: COMPARATOR
Intervention: NaCl aerosol
Number of subjects: 33
Study: 31529447

Group type: EXPERIMENTAL
Intervention: Intracuff pressure of 10 cmH2O
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Intracuff pressure of 30 cmH2O
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Intracuff pressure of 60 cmH2O
Number of subjects: 72

Group type: COMPARATOR
Intervention: Pre-pneumoperitoneum
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Post-pneumoperitoneum
Number of subjects: 72
Study: 30552244

Group type: EXPERIMENTAL
Intervention: Pharmacy-led care
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 60
Study: 27182042

Group type: EXPERIMENTAL
Intervention: liraglutide 0.9 mg/day
Number of subjects: 257

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 257
Study: 25756492

Group type: EXPERIMENTAL
Intervention: Appearance-based educational video
Number of subjects: 50

Group type: COMPARATOR
Intervention: Health-based educational video
Number of subjects: 50
Study: 23859670

Group type: EXPERIMENTAL
Intervention: Adapted Group Motivational Interviewing (AGMI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Community Service (CS)
Number of subjects: 0
Study: 21037100

Group type: EXPERIMENTAL
Intervention: CD8(+) T cells gaining access to lesional epithelium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vascular endothelial expression of mucosal addressin cell adhesion molecule-1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: T cells isolated from dysplastic mucosa
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dysplastic lesions
Number of subjects: 0
Study: 18097503

Group type: EXPERIMENTAL
Intervention: G. lucidum 6 mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: G. lucidum 0.6 mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: G. lucidum 60 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 16855942

Group type: EXPERIMENTAL
Intervention: Diabetics (group I)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Non-diabetics (group II)
Number of subjects: 129
Study: 12631528

Group type: EXPERIMENTAL
Intervention: Alcoholic inpatients
Number of subjects: 28

Group type: COMPARATOR
Intervention: Social drinking controls
Number of subjects: 28
Study: 16464206

Group type: COMPARATOR
Intervention: Generic instruments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diabetes-specific measures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychological measures
Number of subjects: 0
Study: 9381994

Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 21

Group type: COMPARATOR
Intervention: Lovastatin
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 21
Study: 8269452

Group type: EXPERIMENTAL
Intervention: Loratadine (5 or 10 mg once daily for 14 days)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Terfenadine (15 mg twice daily for 14 days)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Loratadine (5 or 10 mg once daily)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Terfenadine (15 mg twice daily)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 96
Study: 4041344

Group type: EXPERIMENTAL
Intervention: Acute administration of nisoldipine
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Continued administration of nisoldipine
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 9
Study: 30509713

Group type: EXPERIMENTAL
Intervention: Saffron supplementation (100 mg/d for 8 weeks)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 26833798

Group type: COMPARATOR
Intervention: First confidence interval approach using Bonferroni adjustment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Second confidence interval approach using randomization tests
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proposed approaches using hypergeometric confidence intervals
Number of subjects: 0
Study: 24386927

Group type: EXPERIMENTAL
Intervention: Telephone-delivered behavioral intervention; 1 session per month for 6 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telephone-delivered behavioral intervention
Number of subjects: 0
Study: 22771173

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Waiting (WAIT for delayed MBCT)
Number of subjects: 91
Study: 20349155

Group type: EXPERIMENTAL
Intervention: Faith community nurse referral
Number of subjects: 100

Group type: COMPARATOR
Intervention: Telephone-assisted physician appointment
Number of subjects: 100
Study: 18672118

Group type: EXPERIMENTAL
Intervention: Electric Vacuum Aspiration (EVA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manual Vacuum Aspiration (MVA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 15922977

Group type: EXPERIMENTAL
Intervention: Ropivacaine
Number of subjects: 170

Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 170
Study: 12478123

Group type: EXPERIMENTAL
Intervention: Extended node dissection
Number of subjects: 123

Group type: COMPARATOR
Intervention: Limited node dissection
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Both extended and limited node dissection
Number of subjects: 123
Study: 10394177

Group type: EXPERIMENTAL
Intervention: Citalopram therapy (40 mg i.v. bolus immediately after admission to the ICU)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Citalopram therapy (continuous infusion over 24 hours)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Citalopram therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group of out-patients
Number of subjects: 0
Study: 8907717

Group type: EXPERIMENTAL
Intervention: Diltiazem administered at 08:00 (AM)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Diltiazem administered at 22:00 (HS)
Number of subjects: 23
Study: 1794358

Group type: EXPERIMENTAL
Intervention: Purified pneumococcal polysaccharide vaccines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Development of more highly immunogenic vaccines (linked polysaccharides to protein carriers)
Number of subjects: 0
Study: 6884024

Group type: EXPERIMENTAL
Intervention: Norinyl
Number of subjects: 0

Group type: COMPARATOR
Intervention: Brevicon
Number of subjects: 0
Study: 31067674

Group type: EXPERIMENTAL
Intervention: Spirulina maxima with PEP (SE)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Placebo with PEP (Ex)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Spirulina maxima without PEP (Sm)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo without PEP (C)
Number of subjects: 52
Study: 29128300

Group type: EXPERIMENTAL
Intervention: Enteral nutrition (20-25 kcal/kg per day)
Number of subjects: 2410

Group type: COMPARATOR
Intervention: Parenteral nutrition (20-25 kcal/kg per day)
Number of subjects: 2410

Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Number of subjects: 2410

Group type: COMPARATOR
Intervention: Parenteral nutrition
Number of subjects: 2410
Study: 25925751

Group type: EXPERIMENTAL
Intervention: Passive heat maintenance (PHM) jacket
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Normal attire and performing 3 × 5 CMJ (NMF)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Combination of PHM and NMF (COMB)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normal-training attire (CON)
Number of subjects: 16
Study: 24220099

Group type: EXPERIMENTAL
Intervention: Six-month multi-strategy programme delivered via playgroups
Number of subjects: 716
Study: 21369791

Group type: EXPERIMENTAL
Intervention: Alendronate (5, 10, or 20 mg daily; 35 mg once-weekly; 35 mg twice-weekly; 70 mg once-weekly)
Number of subjects: 17291

Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 17291

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17291
Study: 20691641

Group type: EXPERIMENTAL
Intervention: Leuprorelin 11.25 mg subcutaneously every 12 weeks
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Leuprorelin
Number of subjects: 204
Study: 19419930

Group type: EXPERIMENTAL
Intervention: Multitargeted therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapies with traditional chemotherapy and radiation therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multitargeted inhibitors
Number of subjects: 0
Study: 16491252

Group type: EXPERIMENTAL
Intervention: Happydent chewing gum (3.38 mg of fluoride as monofluorophosphate)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Trident chewing gum (control)
Number of subjects: 15
Study: 12568272

Group type: EXPERIMENTAL
Intervention: Auricular therapy using magnetic pearls (Group C)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Auricular therapy using Junci Medulla (Group A)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Auricular therapy using Semen Vaccariae (Group B)
Number of subjects: 120
Study: 10792330

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment with low dose ethinyl oestradiol (0.05 microgram/kg/day)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Once daily (OD) injections of GH (6 IU/m2/day)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Twice daily (BID) injections of GH (6 IU/m2/day)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Post-GH treatment with adult dosage of oestrogens
Number of subjects: 19
Study: 8814838

Group type: EXPERIMENTAL
Intervention: Intravesical chemotherapy with epirubicin (20 mg/40 mL saline)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 75
Study: 1495577

Group type: EXPERIMENTAL
Intervention: Antiepileptic therapy using two standard anti-epileptic drugs
Number of subjects: 72121
Study: 6519902

Group type: EXPERIMENTAL
Intervention: Ciclazindol (three different doses)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 31268180

Group type: EXPERIMENTAL
Intervention: Epirubicin, cisplatin and capecitabine (ECX) chemotherapy with bevacizumab (B)
Number of subjects: 1063

Group type: COMPARATOR
Intervention: Epirubicin, cisplatin and capecitabine (ECX) chemotherapy without bevacizumab (B)
Number of subjects: 1063

Group type: EXPERIMENTAL
Intervention: Overall surgical complications
Number of subjects: 1063

Group type: EXPERIMENTAL
Intervention: Respiratory complications
Number of subjects: 1063

Group type: EXPERIMENTAL
Intervention: R1 resection rate
Number of subjects: 1063

Group type: EXPERIMENTAL
Intervention: Lymph node harvest
Number of subjects: 1063
Study: 29801652

Group type: EXPERIMENTAL
Intervention: 90 min cycling at 40% power at maximal aerobic capacity (Pmax) with 15 min passive recovery (90HT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 90 min cycling at 40% Pmax with 15 min CWI recovery (90CWI)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 30 min cycling alternating between 40% and 70% Pmax, with 15 min passive recovery (30HT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Baseline (BASE)
Number of subjects: 30
Study: 26728766

Group type: EXPERIMENTAL
Intervention: CHoBI7 intervention (handwashing with soap and water treatment for 7 days)
Number of subjects: 401

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 401
Study: 23795621

Group type: EXPERIMENTAL
Intervention: MoodGYM (computerized cognitive behavioural therapy)
Number of subjects: 637

Group type: COMPARATOR
Intervention: Informational websites (control)
Number of subjects: 637
Study: 22687889

Group type: COMPARATOR
Intervention: Clarithromycin, amoxicillin and omeprazole (CAO)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Levofloxacin, amoxicillin and omeprazole (LAO)
Number of subjects: 250
Study: 20438568

Group type: EXPERIMENTAL
Intervention: Limited shock wave therapy (SWT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham treatment (control)
Number of subjects: 36
Study: 17642523

Group type: EXPERIMENTAL
Intervention: DHA 900 mg monotherapy for 5 days
Number of subjects: 90

Group type: COMPARATOR
Intervention: DHA 600 mg + mefloquine [MQ] 750 mg combination regimen
Number of subjects: 90
Study: 16036192

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 80
Study: 11942956

Group type: EXPERIMENTAL
Intervention: Cytoreductive nephrectomy (CRN) offered to patients with performance status of 0 or 1.
Number of subjects: 268

Group type: COMPARATOR
Intervention: Conservative treatment for patients with inoperable primary tumors.
Number of subjects: 268

Group type: COMPARATOR
Intervention: Patients with metastatic disease at presentation.
Number of subjects: 268

Group type: COMPARATOR
Intervention: Patients with inoperable primary tumors.
Number of subjects: 268

Group type: COMPARATOR
Intervention: Patients with performance score > or = 2.
Number of subjects: 268
Study: 11991547

Group type: COMPARATOR
Intervention: Leukotriene receptor antagonists
Number of subjects: 0
Study: 9835454

Group type: EXPERIMENTAL
Intervention: 99mTc‐CA
Number of subjects: 20

Group type: COMPARATOR
Intervention: 99mTc‐SC
Number of subjects: 20
Study: 7926288

Group type: EXPERIMENTAL
Intervention: NIDDM patients
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 21
Study: 2780087

Group type: EXPERIMENTAL
Intervention: Arm crank ergometry
Number of subjects: 11

Group type: COMPARATOR
Intervention: Wheelchair treadmill ergometry
Number of subjects: 11
Study: 798708

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 20 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 7021260

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 36

Group type: COMPARATOR
Intervention: Hydrocortisone‐17‐butyrate (HCB)
Number of subjects: 36
Study: 31191105

Group type: EXPERIMENTAL
Intervention: Flywheel resistance exercise training (ETG; n = 18) for 6 weeks (2 to 3 days per week)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Flywheel resistance exercise training (ETG; n = 18)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (CON; n = 18)
Number of subjects: 36
Study: 29023915

Group type: EXPERIMENTAL
Intervention: OCA 10 mg
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: OCA 50 mg
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 27284585

Group type: EXPERIMENTAL
Intervention: Chlorhexidine-fluoride varnish (CHX-F)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Chlorhexidine-thymol varnish (CHX-T)
Number of subjects: 57
Study: 23963269

Group type: EXPERIMENTAL
Intervention: Athletes with low back pain
Number of subjects: 44

Group type: COMPARATOR
Intervention: Healthy athletes (control group)
Number of subjects: 44